Article
Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: computed efficacy, effectiveness and impact.
International journal of oncology - 1 Jan 2001
Eisinger F, Charafe-Jauffret E, Jacquemier J, Birnbaum D, Julian-Reynier C, Sobol H
Abstract excerpt
The management of breast cancer prone women remains a tough issue despite the release of institutional guidelines. Currently, only the anti-estrogen agent Tamoxifen and prophylactic surgery are claimed to decrease breast cancer incidence. However, efficacy of Tamoxifen, particularly in BRCA1 gene carriers, remains controversial and acceptability of prophylactic surgery is low. To evaluate the expected impact of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.